



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Chikara MURAKATA et al. **Confirmation No. : 4996**
Group Art Unit: 1614
Serial No : 10/560,230
(National Stage of PCT/JP2004/008375)
Examiner: not yet assigned
I.A. Filed : June 9, 2004)
For : THIADIAZOLINE DERIVATIVE

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Further to the Information Disclosure Statement filed December 1, 2006 and April 10, 2007, and in accordance with the duty of disclosure under 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98, Applicants hereby direct the Examiner's attention to the following documents, which were cited the Partial European Search Report with respect to European Application EP 04792510.2, which is a family member of copending Application No. 10/575,093.

- (1) EP 0 207 004 A, December 12, 1986, including an English language abstract;
- (2) U.S. Patent No. 4,699,913 (Farooq et al.), October 13, 1987; Applicants note that this document is a family member of document (1);
- (3) D.M. Evans et al., Journal of the Chemical Society, Perkin Transactions 1, 1986, Vol. 8, pp. 1499-1505; and
- (4) K. Zelenin et al., Chemical Abstracts, 1982, Vol. 97, No. 19, p. 708, Abstract No. 162877w.


Copies of the above-listed documents (with exception of the U.S. patent), and the Supplementary Partial European Search Report with respect to EP 04792510.2 are enclosed together with a completed copy of the PTO-1449 Form listing the above-noted documents. The Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Further to 37 C.F.R. §1.98 (a)(2)(ii) and to the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. §1.98 (a)(2)(iii) if a U.S. patent application was filed after June 30, 2003, a copy of the U.S. patent is not enclosed herewith. However, if a copy is needed, the Examiner is respectfully requested to contact the undersigned.

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

If there are any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Chikara MURAKATA et al.


Bruce H. Bernstein
Reg. No. 29,027 42,920

May 9, 2007
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

FORM PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.
P28933

Application No.
10/560,230

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant
Chikara MURAKATA et al.

I.A. Filing Date
June 9, 2004

Group
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4 6 9 9 9 1 3	10/13/87	FAROOQ et al.			
.							
1							

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	D.M. Evans et al., Journal of the Chemical Society, Perkin Transactions 1, 1986, Vol. 8, pp. 1499-1505.
	2	K. Zelenin et al., Chemical Abstracts, 1982, Vol. 97, No. 19, p. 708, Abstract No. 162877w.
	4	English language abstract of EP 0207004.

EXAMINER

DATE CONSIDERED _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.